IN2014DN10390A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10390A
IN2014DN10390A IN10390DEN2014A IN2014DN10390A IN 2014DN10390 A IN2014DN10390 A IN 2014DN10390A IN 10390DEN2014 A IN10390DEN2014 A IN 10390DEN2014A IN 2014DN10390 A IN2014DN10390 A IN 2014DN10390A
Authority
IN
India
Prior art keywords
human patient
nucleotides
treating
lung cancer
small cell
Prior art date
Application number
Other languages
English (en)
Inventor
Chen Duksin
Shoshi Tessler
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IN2014DN10390A publication Critical patent/IN2014DN10390A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN10390DEN2014 2012-05-18 2013-05-17 IN2014DN10390A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261649092P 2012-05-18 2012-05-18
PCT/US2013/041652 WO2013173757A1 (en) 2012-05-18 2013-05-17 Method for treating non-small cell lung cancer

Publications (1)

Publication Number Publication Date
IN2014DN10390A true IN2014DN10390A (enrdf_load_stackoverflow) 2015-08-14

Family

ID=49581824

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10390DEN2014 IN2014DN10390A (enrdf_load_stackoverflow) 2012-05-18 2013-05-17

Country Status (17)

Country Link
US (1) US20130310440A1 (enrdf_load_stackoverflow)
EP (1) EP2849761A1 (enrdf_load_stackoverflow)
JP (1) JP2015522542A (enrdf_load_stackoverflow)
KR (1) KR20150024843A (enrdf_load_stackoverflow)
CN (1) CN104684564A (enrdf_load_stackoverflow)
AR (1) AR091090A1 (enrdf_load_stackoverflow)
AU (1) AU2013262589A1 (enrdf_load_stackoverflow)
BR (1) BR112014028787A2 (enrdf_load_stackoverflow)
CA (1) CA2874092A1 (enrdf_load_stackoverflow)
EA (1) EA201492148A1 (enrdf_load_stackoverflow)
IL (1) IL235459A0 (enrdf_load_stackoverflow)
IN (1) IN2014DN10390A (enrdf_load_stackoverflow)
PH (1) PH12014502569A1 (enrdf_load_stackoverflow)
SG (1) SG11201407649RA (enrdf_load_stackoverflow)
TW (1) TW201402132A (enrdf_load_stackoverflow)
UY (1) UY34812A (enrdf_load_stackoverflow)
WO (1) WO2013173757A1 (enrdf_load_stackoverflow)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1163254T3 (da) 1999-02-26 2008-06-09 Univ British Columbia TRPM-2 antisense-behandling
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
EP2569618B1 (en) 2010-05-08 2017-03-01 The Regents of the University of California Sem scanner sensing apparatus, system and methodology for early detection of ulcers
EP2685990A4 (en) 2011-03-15 2014-09-17 Univ British Columbia COMBINATION OF AN ANTI-CLUSTERIN OLIGONUCLEOTIDE AND AN HSP90 INHIBITOR FOR THE TREATMENT OF PROSTATE CANCER
CN104473973B (zh) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 一株戈氏梭菌驯化株的应用
WO2016172263A1 (en) 2015-04-24 2016-10-27 Bruin Biometrics Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
CN118177725A (zh) 2017-02-03 2024-06-14 布鲁恩医疗创新有限责任公司 糖尿病足溃疡易感性的测量
EP3515298A4 (en) 2017-02-03 2020-03-11 Bruin Biometrics, LLC MEASUREMENT OF EDEMA
PL3515296T3 (pl) 2017-02-03 2024-03-25 Bbi Medical Innovations, Llc Pomiar żywotności tkanki
JP7209713B2 (ja) 2017-11-16 2023-01-20 ブルーイン、バイオメトリクス、リミテッド、ライアビリティー、カンパニー 表皮下水分値を用いた褥瘡性潰瘍の戦略的処置
WO2019136287A1 (en) * 2018-01-05 2019-07-11 LifeUnit Inc. Adjuvant chemicals that prevent drug tolerance and persister formation by bacteria
PT3749181T (pt) 2018-02-09 2024-05-15 Bruin Biometrics Llc Deteção de lesões nos tecidos
IL290883B2 (en) 2018-10-11 2024-02-01 Bruin Biometrics Llc Device with disposable element
US11642075B2 (en) 2021-02-03 2023-05-09 Bruin Biometrics, Llc Methods of treating deep and early-stage pressure induced tissue damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
EP2300825A4 (en) * 2008-06-18 2012-04-25 Abbott Lab P / GF 1 COMPARATIVE DIAGNOSTIC PROCEDURES AND PRODUCTS
SG194931A1 (en) * 2011-05-19 2013-12-30 Teva Pharma Method for treating non-small cell lung cancer

Also Published As

Publication number Publication date
CN104684564A (zh) 2015-06-03
TW201402132A (zh) 2014-01-16
AU2013262589A1 (en) 2015-01-22
AR091090A1 (es) 2014-12-30
US20130310440A1 (en) 2013-11-21
PH12014502569A1 (en) 2015-01-21
WO2013173757A8 (en) 2015-04-30
KR20150024843A (ko) 2015-03-09
UY34812A (es) 2013-12-31
JP2015522542A (ja) 2015-08-06
BR112014028787A2 (pt) 2017-06-27
SG11201407649RA (en) 2014-12-30
IL235459A0 (en) 2014-12-31
EA201492148A1 (ru) 2015-04-30
EP2849761A1 (en) 2015-03-25
CA2874092A1 (en) 2013-11-21
WO2013173757A1 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
IN2014DN10390A (enrdf_load_stackoverflow)
PH12013502402A1 (en) Method for treating non-small cell lung cancer
NZ603901A (en) Vectors and sequences for the treatment of diseases
NZ715081A (en) Antisense oligomers and conjugates targeting pcsk9
MX2015011943A (es) Acidos ribonucleicos con nucleotidos modificados por 4'-tio y metodos relacionados.
EP3698631A3 (en) Methods of delivering oligonucleotides to immune cells
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
NZ741397A (en) Oligonucleotide compositions and methods thereof
UA117098C2 (uk) Сполука, що містить модифікований олігонуклеотид
PH12015501953A1 (en) Substituted nucleotide analogs
MX359548B (es) Agentes de iarn modificados.
EA201490563A1 (ru) Антисмысловые олигонуклеотиды для лечения врожденного амавроза лебера
MX2010003299A (es) Oligonucleotidos muy cortos (micromirs).
NZ630914A (en) Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
WO2011121453A3 (en) Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
TN2015000079A1 (en) Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
MX2013005875A (es) Inhibidores de microarn que comprenden nucleotidos bloqueados.
AU2009279857A8 (en) Modulation of toll-like receptor 3 expression by antisense oligonucleotides
BR112013002738A2 (pt) métodos e compostos para o diagnóstico e o tratamento do câncer
BR112019008810A2 (pt) micrornas modificadas com 5-halouracila e seu uso no tratamento de câncer
WO2011021177A3 (en) Compositions and methods for prognosis and treatment of prostate cancer
WO2015032800A3 (en) Compositions and methods for inducing senescence in cancer cells
IN2014CN03921A (enrdf_load_stackoverflow)
WO2012145597A3 (en) Recombinant virus products and methods for inhibition of expression of myotilin
MX2013003698A (es) Agente preventivo o terapeutico contra la fibrosis.